Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Ensysce Biosciences
(OTC:ENSCW)
Intraday
$0.03
0
[0.00%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$0.03
0
[0.00%]
Last update: 1:22PM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Ensysce Biosciences Stock (OTC:ENSCW)
Ensysce Biosciences Stock (OTC: ENSCW)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, October 24, 2023
Ensysce Biosciences Secures $1.7M Convertible Note Financing
Happy Mohamed
-
Oct 24, 2023, 8:25AM
Monday, December 19, 2022
Ensysce Biosciences Announces Data From PF614-MPAR-101-Part A Successfully Demonstrating Opioid Overdose Protection
Benzinga Newsdesk
-
Dec 19, 2022, 8:13AM
Monday, December 05, 2022
Ensysce Biosciences Announces Completion Of Clinical Portion Of Overdose Protection Trial PF614-MPAR-101-Part A
Benzinga Newsdesk
-
Dec 5, 2022, 8:11AM
Monday, November 14, 2022
Ensysce Biosciences Announces FDA Guidance On The Clinical Development Pathway For PF614
Benzinga Newsdesk
-
Nov 14, 2022, 8:08AM
Monday, October 31, 2022
Ensysce Biosciences Announces Topline Results Of Clinical Study Evaluating Human Abuse Potential Of Intranasal Administration Of PF614, A TAAP Abuse-Deterrent Oxycodone Extended-Release Product
Benzinga Newsdesk
-
Oct 31, 2022, 8:13AM
Friday, October 28, 2022
Ensysce Biosciences Announces First Subjects Dosed In Second Human Abuse Potential Study
Benzinga Newsdesk
-
Oct 28, 2022, 9:41AM
Thursday, September 22, 2022
Ensysce Biosciences Announces Initiation Of Second Human Abuse Potential Study, Being Conducted By Dr. Vince Clinical Research
Benzinga Newsdesk
-
Sep 22, 2022, 8:09AM
Thursday, September 08, 2022
Ensysce Biosciences Announces Results of Special Meeting of Stockholders
Benzinga Newsdesk
-
Sep 8, 2022, 4:21PM
Wednesday, August 31, 2022
Ensysce Biosciences And Quotient Sciences Announce A Partnership On The Development And Clinical Testing Of Ensysce's PF614-MPAR, A Novel Opioid Designed To Prevent Abuse And Overdose
Benzinga Newsdesk
-
Aug 31, 2022, 1:43PM
Wednesday, July 13, 2022
Ensysce Biosciences Announces Initial Patients Dosed Of First Human Abuse Potential Study
Bill Haddad
-
Jul 13, 2022, 4:08PM
Ensysce Biosciences Announces Initial Patients Dosed Of First Human Abuse Potential Study
Bill Haddad
-
Jul 13, 2022, 4:08PM
Monday, May 23, 2022
Ensysce Biosciences Announces Initiation Of First Human Abuse Potential Study
Benzinga Newsdesk
-
May 23, 2022, 4:17PM
Thursday, May 05, 2022
Ensysce Biosciences Announces New Clinical Results From Trials PF614-102 And PF614-MPAR-101
Benzinga Newsdesk
-
May 5, 2022, 9:16AM
Monday, January 10, 2022
Ensysce Biosciences Announces First Cohort Dosing In Bioequivalence Study Of Novel 'TAAP' Opioid
Benzinga Newsdesk
-
Jan 10, 2022, 8:17AM
Tuesday, January 04, 2022
Ensysce Biosciences Reports Achieved Successful Completion Of Part A Of Multiple-Ascending Dose/Bioequivalents Trial For PF614
Benzinga Newsdesk
-
Jan 4, 2022, 8:02AM
Wednesday, December 15, 2021
Ensysce Biosciences Announces First Patients Enrolled In Phase 1 Study Of PF614-MPAR, Its Unique Technology Platform To Provide Opioid Overdose Protection
Benzinga Newsdesk
-
Dec 15, 2021, 4:09PM
Tuesday, November 30, 2021
Ensysce Biosciences Announces Clinical Trial Progress Of Its New Class Of Opioids
Benzinga Newsdesk
-
Nov 30, 2021, 8:06AM
Thursday, August 05, 2021
Ensysce Biosciences Highlights Notice Of Allowance From US Patent & Trademark Office For 'Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof'
Benzinga Newsdesk
-
Aug 5, 2021, 8:18AM
Thursday, July 01, 2021
Ensysce Biosciences To Begin Trading On Nasdaq On July 2
Benzinga Newsdesk
-
Jul 1, 2021, 4:41PM